EGFR and glioblastoma: Given that alterations affecting EGFR, e.g. EGFR overexpression, have been identified previously in tumors of patients with GBM, including in long-term responders to afatinib [16, 17, 44, 46], a potential limitation of the present study is that patients were not selected based on biomarker analysis.